The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID?

Morton J Cowan

doi:10.1080/1744666X.2016.1216317

The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID?

Expert Rev Clin Immunol. 2016 Oct;12(10):1007-9. doi: 10.1080/1744666X.2016.1216317. Epub 2016 Jul 29.

Author

Morton J Cowan¹

Affiliation

¹ a UCSF Department of Pediatrics , Allergy, Immunology, and Blood and Marrow Transplant Division , San Francisco , CA , USA.

No abstract available

Keywords: Primary immune deficiency; SCID; Wiskott Aldrich syndrome; chronic granulomatous disease; enzyme replacement therapy; gene therapy; hematopoietic cell transplantation.

Publication types

Consensus Development Conference, NIH
Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Genetic Therapy*
Granulomatous Disease, Chronic / therapy*
Hematopoietic Stem Cell Transplantation*
Humans
Immunologic Deficiency Syndromes / therapy*
National Institute of Allergy and Infectious Diseases (U.S.)
Patient Advocacy
United States
Wiskott-Aldrich Syndrome / therapy*

Publication types

MeSH terms

Grants and funding